Q-omics provides the consensus-scored GEMIN7P1 profile across patient tissues and cancer cell-line models. GEMIN7P1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, GEMIN7P1 is differentially expressed in 3, with the highest sampling consensus in KICH. Additionally, GEMIN7P1 RNA expression shows 5,202 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight DLBC, KICH, and STAD as cancer lineages where GEMIN7P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GEMIN7P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GEMIN7P1 survival associations across molecular data types. GEMIN7P1 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GEMIN7P1 RNA expression–survival associations across cancer types. High GEMIN7P1 expression shows unfavorable associations in DLBC, STAD, ESCA, BLCA and BRCA, but favorable associations in KIRP. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for GEMIN7P1 RNA expression.
This table summarizes GEMIN7P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for GEMIN7P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GEMIN7P1 shows lower tumor expression in KICH and higher tumor expression in BRCA and STAD. The KICH box plot shows higher GEMIN7P1 RNA expression in normal versus tumor tissue (log2 FC = −0.105, t-test p = .034).
This table shows molecular features associated with GEMIN7P1 in patient tissues and cancer cell lines. In patient samples, GEMIN7P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
